Newsletter Tool

Featured Story

Moderna banks $3.3B in latest COVID-19 vaccine supply deal with US, rounding out government’s earmarked doses

By Noah Higgins-Dunn

The U.S. will pay Moderna $3.3 billion for 200 million additional COVID-19 vaccine doses, as announced last week. That brings the country's total supply to 500 million, which is the amount Moderna earmarked for the U.S. back in August.

Medicaid enrollment swells under pandemic, hitting nearly 74M

By Paige Minemyer

Medicaid enrollment grew significantly under the pandemic, according to new data from the Biden administration.

Novavax's COVID-19 shot won't see much U.S. use, but a big global market awaits: analyst

By Kevin Dunleavy

Because of development delays, Novavax should expect little uptake for its COVID-19 vaccine in the United States. But there's still a ready market globally, which the shot is well equipped to serve, GlobalData analysts report.

Moove over IPO: SAB Biotherapeutics to milk the stock market via SPAC

By Amirah Al Idrus

After grabbing government grants to develop its polyclonal antibody treatment for COVID-19, SAB Biotherapeutics is going public through a $118 million SPAC merger. The proceeds will bankroll a pipeline of treatments for various diseases that are produced by and extracted from genetically modified cows.

Nursing home deaths spiked 32% among Medicare beneficiaries during 2020, OIG finds

By Dave Muoio

More than 2 in 5 beneficiaries living in a nursing home were diagnosed with confirmed or likely COVID-19, with nonwhite and dual-eligible beneficiaries being hit the hardest, according to the government watchdog.

COVID-19 tracker: White House to miss July 4 vaccination goal; Delta variant 'greatest threat' to US response, Fauci says

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

The Biden administration said it will likely miss its goal of administering one dose of vaccine to 70% of adult Americans by the Fourth of July. And more headlines.

Sanofi, Translate Bio start seasonal mRNA flu vaccine trial, gaining early lead over Moderna and Pfizer

By Nick Paul Taylor

Sanofi and Translate Bio have started a phase 1 clinical trial of an mRNA vaccine for seasonal influenza. The initiation of the study puts the partners ahead of Moderna and Pfizer in the race to show mRNA vaccines are as good or better at preventing flu than existing technologies.

COVID-19 Tracker